US incentive scheme for neglected diseases: A good

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Doshi, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MILTEFOSINE;

COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; LEISHMANIASIS; NEGLECTED DISEASE; POLITICAL SYSTEM; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; RISK BENEFIT ANALYSIS; UNITED STATES; VISCERAL LEISHMANIASIS; WORLD HEALTH ORGANIZATION;

EID: 84904489224     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4665     Document Type: Review

References (7)

1. Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff 2006;25:313-24. (Pubitemid 43529539)
2. TDR. Bangladesh beats a deadly scourge, 19 May 2014. www.who.int/tdr/ news/2014/deadly-scourge/en/.
3. Æterna Zentaris receives regulatory approval for Impavido® in Germany. Press release, 6 December 2004. www.aezsinc.com/en/page.php?p=60&q= 103.
4. TDR. Visceral leishmaniasis elimination. Draft business plan for JCB. 2007. www.who.int/tdr/publications/documents/bl10-business-plan.pdf?ua=1.
5. Shamsuddin H. FDA medical review of application number 204684Orig1s000 IMPAVIDO (miltefosine). 2014. www.accessdata.fda.gov/drugsatfda-docs/nda/2014/ 204684Orig1s000MedR.pdf.
6. Bryceson ADM. Preface. Trans R Soc Trop Med Hyg 2006;100(suppl):S1-S3. (Pubitemid 44490167)
7. Ridley DB, Sánchez AC. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet 2010;376:922-7.